ACP: Lessons Learned during COVID-19 Pandemic

ACIP Recommends 2nd COVID-19 Shot for Older Adults, Immunocompromised Individuals

Article

Rochelle Walensky, MD MPH, Director of the US Centers for Disease Control and Prevention (CDC), was a featured presenter at the recent American College of Physicians Internal Medicine Meeting 2021: Virtual Experience. In her presentation, titled "COVID-19: Lessons Learned," Dr Walensky discussed racial/ethnic inequities in COVID-19 impact, breakthrough infections, what happened with the Johnson & Johnson vaccine, and variants of concern in the US.

The slide show that follows is based on Dr Walensky's presentation and includes links to all of the primary studies that she discusses.

Related Content

October 24th 2024

Respiratory Tripledemic 2022-23: An Expert Recap

CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.

April 6th 2023

Pfizer-BioNTech COVID-19 Vaccine May Reduce Risk of Long COVID in Older Adults

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

October 21st 2024

Cold & Flu Season 2022-23: AAFP Board Chair Shares Concerns

IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.

October 25th 2022

Remdesivir Plus Dexamethasone Reduces Mortality Risk among Adults Hospitalized with COVID-19

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with American Academy of Family Physicians Board Chair Sterling Ransone, Jr, MD.

October 10th 2024

COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types

Remdesivir plus dexamethasone was associated with reduced 14- and 28-day mortality vs dexamethasone alone, according to a large study of adults hospitalized with COVID-19.

October 9th 2024

ACIP Recommends 2nd COVID-19 Shot for Older Adults, Immunocompromised Individuals

Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.

Related Content

October 24th 2024

Respiratory Tripledemic 2022-23: An Expert Recap

CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.

April 6th 2023

Pfizer-BioNTech COVID-19 Vaccine May Reduce Risk of Long COVID in Older Adults

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

October 21st 2024

Cold & Flu Season 2022-23: AAFP Board Chair Shares Concerns

IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.

October 25th 2022

Remdesivir Plus Dexamethasone Reduces Mortality Risk among Adults Hospitalized with COVID-19

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with American Academy of Family Physicians Board Chair Sterling Ransone, Jr, MD.

October 10th 2024

COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types

Remdesivir plus dexamethasone was associated with reduced 14- and 28-day mortality vs dexamethasone alone, according to a large study of adults hospitalized with COVID-19.

October 9th 2024